Jazz Set To Expand Ziihera Market In Gastroesophageal Cancer

 
• By Alaric DeArment
  
Jazz Pharmaceuticals
Jazz announced positive results from its Phase III trial of Ziihera in gastroesophageal adenocarcinoma. (Shutterstock)

More from Clinical Trials

More from R&D